Last updated: February 17, 2026
What is NDC 00013-2651?
NDC 00013-2651 refers to Prolia (denosumab), a monoclonal antibody used primarily for the treatment of osteoporosis in postmenopausal women and adults at high fracture risk. It is marketed by Amgen Inc.
Market Overview
Indications and Market Demand
Prolia's approval covers multiple indications:
- Osteoporosis in women and men
- Glucocorticoid-induced osteoporosis
- Bone loss associated with cancer treatments
The increasing aging population, especially postmenopausal women, drives the demand for osteoporosis treatments. The global osteoporosis drugs market was valued at approximately USD 8.2 billion in 2022, projected to grow at a CAGR of 3.5% through 2030.
Competitive Landscape
Key competitors include:
- Bazedoxifene (Eli Lilly)
- Zoledronic acid (Novartis, Teva)
- Romosozumab (Amgen's own product for osteoporosis)
Prolia’s main differentiator is its subcutaneous administration every six months, enhancing patient compliance compared to bisphosphonates requiring weekly or monthly dosing.
Market Penetration and Adoption
Prolia has a high adoption rate in clinics specializing in osteoporosis management. Insurance reimbursements and physician familiarity support continued market penetration.
Geographic Outlook
The U.S. accounts for approximately 70% of sales, with growing markets in Europe and Asia. China’s osteoporosis market, with an aging population, offers future growth potential, though local competition and regulatory hurdles exist.
Price Analysis and Projections
Current Pricing Data
As of early 2023, the average wholesale price (AWP) for a Prolia injection is approximately USD 1,350 per dose. With the dosing schedule being two doses per year, annual treatment costs to the provider or patient approximate USD 2,700.
Reimbursement and Cost Dynamics
Insurance coverage typically covers most of the cost in the U.S., but patient co-pays influence market accessibility. Price negotiations and rebates diminish the net price received by manufacturers.
Future Price Trends
Price adjustments tend to follow:
- Inflation-related increases due to manufacturing and distribution costs.
- Competitive pressure from biosimilars and new therapies.
- Regulatory and policy changes affecting drug pricing.
Based on past trends, annual list prices for biologics like Prolia have increased roughly 3% annually over the past five years.
Biosimilar Impact and Price Compression
Amgen’s patent protections for Prolia expire in the U.S. in 2025, opening the market to biosimilars. Competitors could introduce biosimilar denosumab products with prices 20-40% lower initially, leading to significant discounts and market share shifts.
===
Projected Market and Pricing Outlook (2023–2030)
| Year |
Estimated Market Size (USD Billions) |
% Growth |
Price Trend |
Key Factors |
| 2023 |
1.8 |
4% |
+3% annually |
Steady demand, patent exclusivity |
| 2025 |
2.0 |
11% |
Potential slight decrease due to biosimilars |
Biosimilar entry, price competition |
| 2026 |
2.2 |
10% |
Stabilization after biosimilar adoption |
Biosimilar market penetration |
| 2028 |
2.5 |
9% |
Possible price reductions in biosimilar segment |
Market saturation, generic competition |
| 2030 |
2.8 |
10% |
Continued price pressure |
Increased biosimilar options, new indications |
Note: These projections assume steady growth in osteoporosis prevalence, ongoing payer coverage, and biosimilar market entry around 2025.
Key Takeaways
- NDC 00013-2651 (Prolia) remains a leading monoclonal antibody in osteoporosis, with high market share in the U.S.
- Current pricing averages USD 1,350 per dose, with annual treatment costs around USD 2,700.
- Market growth is driven by an aging population and expanding indications, particularly in oncology-related bone health.
- Patent expiration in 2025 will introduce biosimilar competition, likely reducing prices by 20-40%.
- Long-term market outlook involves stabilization and potential consolidation as biosimilars gain traction and new therapies emerge.
FAQs
1. When will biosimilars for Prolia hit the market?
Biosimilars for denosumab are expected to enter the U.S. market after patent expiration around 2025, with availability possibly earlier in other regions.
2. How will biosimilar entry impact pricing?
Biosimilars typically reduce list prices initially by 20-40%, increasing price competition and leading to lower treatment costs.
3. Are there indications other than osteoporosis that affect market size?
Yes. Prolia’s approvals for glucocorticoid-induced osteoporosis and cancer-related bone loss expand its target population, supporting revenue streams.
4. What are the key factors influencing future price trends?
Regulatory policies, biosimilar adoption rates, manufacturing costs, and payer negotiations primarily influence future prices.
5. How significant is the oncology segment for Prolia?
While initially approved for osteoporosis, Prolia's role in cancer-related bone loss management is growing, particularly in breast and prostate cancer patients.
References
[1] MarketWatch. "Osteoporosis Drugs Market Size & Trends," 2022.
[2] Amgen Inc. Annual Reports, 2022.
[3] IQVIA. "Biologic Price Trends," 2022.
[4] FDA. "Biosimilar Denosumab Approvals," 2022.
[5] EvaluatePharma. "Pipeline and Competitive Landscape," 2023.
